Form 4 for TBPH Theravance Biopharma, Inc.
Accepted 2022-03-01 00:00:00 ET · period of report 2022-02-25 · accession 0001415889-22-002078 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-01 | 2022-02-25 | TBPH | Winningham Rick E | CEO, Dir | A - Grant | $0.00 | +170.0K | 1.45M | +13% | $0 |
| D | 2022-03-01 | 2022-02-25 | TBPH | Winningham Rick E | CEO, Dir | A - Grant | $0.00 | +515.0K | 515.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2022-02-25 | A | A | 170,000 | $0.00 | 1,449,300 | D | — | — | |
| 2 | Derivative | Share Option (Right to Buy) | 2022-02-25 | A | A | 515,000 | $0.00 | 515,000 | D | $10.24 · — to 2032-02-24 | 515,000 Ordinary Shares | (F1) 25% of this option may be exercised when the optionee completes 12 months of continuous Service after the Date of Grant. Any remaining unvested shares may be exercised with respect to an additional 1/48th of the shares subject to the option when the optionee completes each month of continuous Service thereafter. |